Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese
Objective: Metabolic and other medical conditions are frequently comorbid with schizophrenia. As they might be the side-effects of antipsychotic treatment, studying first-episode drug-naïve schizophrenia (FDSZ) provides a unique opportunity to investigate a direct pathogenic link between metabolic c...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.702720/full |
| _version_ | 1819149184693960704 |
|---|---|
| author | Qi Zhang Qi Zhang Qi Zhang Hui He Hui He Xia Bai Xia Bai Xia Bai Liping Jiang Liping Jiang Wei Chen Wei Chen Xiaoying Zeng Xiaoying Zeng Xiaoying Zeng Yanjia Li Yanjia Li Yanjia Li Antonio L. Teixeira Jing Dai Jing Dai Jing Dai |
| author_facet | Qi Zhang Qi Zhang Qi Zhang Hui He Hui He Xia Bai Xia Bai Xia Bai Liping Jiang Liping Jiang Wei Chen Wei Chen Xiaoying Zeng Xiaoying Zeng Xiaoying Zeng Yanjia Li Yanjia Li Yanjia Li Antonio L. Teixeira Jing Dai Jing Dai Jing Dai |
| author_sort | Qi Zhang |
| collection | DOAJ |
| description | Objective: Metabolic and other medical conditions are frequently comorbid with schizophrenia. As they might be the side-effects of antipsychotic treatment, studying first-episode drug-naïve schizophrenia (FDSZ) provides a unique opportunity to investigate a direct pathogenic link between metabolic changes and schizophrenia. Here, we presented the methods and baseline unique metabolic profile of FDSZ patients without medical comorbidities unveiling subthreshold indices of metabolic disturbances.Method: Drug-naïve individuals diagnosed with schizophrenia but without any previous medical conditions were invited to participate in the study. Participants were submitted to structured psychiatric and cognitive assessments, laboratory and neuroimaging tests. Subjects will be followed after antipsychotic treatment at 6, 24 and 48 weeks.Results: During an 8-month-period, out of 103 patients presenting with first episode psychosis, 67 subjects (43.3% men, 56.7% women) were enrolled in the study. They had a mean ± SD age of 32.1 ± 8.7 years, with a mean BMI of 21.1 kg/m2 and 11.3 ± 3.6 years of schooling. Less than 1/3 reported a family history of mental illness. Upon laboratory assessment, 10.4%, 7.5%, and 11.9% of patients were identified with hyperhomocysteinemia, hypertriglyceridemia and hyperprolactinemia, respectively, with percentages of women relatively higher than men except for hypertriglyceridemia.Conclusions: First episode schizophrenia patients, especially women, present subclinical metabolic abnormalities, independent of antipsychotic treatment. |
| first_indexed | 2024-12-22T13:57:35Z |
| format | Article |
| id | doaj.art-34d7786f3d5940fda43a7c9e732a7447 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-22T13:57:35Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-34d7786f3d5940fda43a7c9e732a74472022-12-21T18:23:31ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402021-07-011210.3389/fpsyt.2021.702720702720Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han ChineseQi Zhang0Qi Zhang1Qi Zhang2Hui He3Hui He4Xia Bai5Xia Bai6Xia Bai7Liping Jiang8Liping Jiang9Wei Chen10Wei Chen11Xiaoying Zeng12Xiaoying Zeng13Xiaoying Zeng14Yanjia Li15Yanjia Li16Yanjia Li17Antonio L. Teixeira18Jing Dai19Jing Dai20Jing Dai21The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, ChinaChengdu Forth People' s Hospital, Chengdu Mental Health Center, Chengdu, ChinaThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, ChinaChengdu Forth People' s Hospital, Chengdu Mental Health Center, Chengdu, ChinaThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, ChinaChengdu Forth People' s Hospital, Chengdu Mental Health Center, Chengdu, ChinaThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, ChinaChengdu Forth People' s Hospital, Chengdu Mental Health Center, Chengdu, ChinaThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, ChinaChengdu Forth People' s Hospital, Chengdu Mental Health Center, Chengdu, ChinaThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, ChinaChengdu Forth People' s Hospital, Chengdu Mental Health Center, Chengdu, ChinaNeuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, United StatesThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, ChinaChengdu Forth People' s Hospital, Chengdu Mental Health Center, Chengdu, ChinaNeuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, United StatesChengdu Medical College School of Nursing, Chengdu, ChinaThe Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, University of Electronic Science and Technology of China, Chengdu, ChinaSchool of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, ChinaChengdu Forth People' s Hospital, Chengdu Mental Health Center, Chengdu, ChinaObjective: Metabolic and other medical conditions are frequently comorbid with schizophrenia. As they might be the side-effects of antipsychotic treatment, studying first-episode drug-naïve schizophrenia (FDSZ) provides a unique opportunity to investigate a direct pathogenic link between metabolic changes and schizophrenia. Here, we presented the methods and baseline unique metabolic profile of FDSZ patients without medical comorbidities unveiling subthreshold indices of metabolic disturbances.Method: Drug-naïve individuals diagnosed with schizophrenia but without any previous medical conditions were invited to participate in the study. Participants were submitted to structured psychiatric and cognitive assessments, laboratory and neuroimaging tests. Subjects will be followed after antipsychotic treatment at 6, 24 and 48 weeks.Results: During an 8-month-period, out of 103 patients presenting with first episode psychosis, 67 subjects (43.3% men, 56.7% women) were enrolled in the study. They had a mean ± SD age of 32.1 ± 8.7 years, with a mean BMI of 21.1 kg/m2 and 11.3 ± 3.6 years of schooling. Less than 1/3 reported a family history of mental illness. Upon laboratory assessment, 10.4%, 7.5%, and 11.9% of patients were identified with hyperhomocysteinemia, hypertriglyceridemia and hyperprolactinemia, respectively, with percentages of women relatively higher than men except for hypertriglyceridemia.Conclusions: First episode schizophrenia patients, especially women, present subclinical metabolic abnormalities, independent of antipsychotic treatment.https://www.frontiersin.org/articles/10.3389/fpsyt.2021.702720/fullfirst-episode drug-naï ve schizophreniametabolic abnormalitiesHomocysteinetriglycerideprolactin |
| spellingShingle | Qi Zhang Qi Zhang Qi Zhang Hui He Hui He Xia Bai Xia Bai Xia Bai Liping Jiang Liping Jiang Wei Chen Wei Chen Xiaoying Zeng Xiaoying Zeng Xiaoying Zeng Yanjia Li Yanjia Li Yanjia Li Antonio L. Teixeira Jing Dai Jing Dai Jing Dai Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese Frontiers in Psychiatry first-episode drug-naï ve schizophrenia metabolic abnormalities Homocysteine triglyceride prolactin |
| title | Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese |
| title_full | Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese |
| title_fullStr | Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese |
| title_full_unstemmed | Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese |
| title_short | Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese |
| title_sort | unveiling the metabolic profile of first episode drug naive schizophrenia patients baseline characteristics of a longitudinal study among han chinese |
| topic | first-episode drug-naï ve schizophrenia metabolic abnormalities Homocysteine triglyceride prolactin |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2021.702720/full |
| work_keys_str_mv | AT qizhang unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT qizhang unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT qizhang unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT huihe unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT huihe unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT xiabai unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT xiabai unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT xiabai unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT lipingjiang unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT lipingjiang unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT weichen unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT weichen unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT xiaoyingzeng unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT xiaoyingzeng unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT xiaoyingzeng unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT yanjiali unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT yanjiali unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT yanjiali unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT antoniolteixeira unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT jingdai unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT jingdai unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese AT jingdai unveilingthemetabolicprofileoffirstepisodedrugnaiveschizophreniapatientsbaselinecharacteristicsofalongitudinalstudyamonghanchinese |